Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial.
By B. Burmeister, B. Smithers, V. Gebski, L. Fitzgerald, R. Simes, P. Devitt, S. Ackland, D. Gotley, D. Joseph, J. Millar and 3 more. The Lancet Oncology, 2005
924 citations recorded by the source corpus.
Subfields: Pulmonary and Respiratory Medicine, Surgery
View Paper: https://www.semanticscholar.org/paper/a05789834aee6c88ba6e5fa8d59b9b5164df12e4
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
Citations in the corpus
- Neoadjuvant Chemoradiotherapy Followed by Surgery Versus Surgery Alone for Locally Advanced Squamous Cell Carcinoma of the Esophagus (NEOCRTEC5010): A Phase III Multicenter, Randomized, Open-Label Clinical Trial (2018, background): “The sample size of ESCC was relatively small in most trials(5-11); there were usually no more than 80 cases of patients with ESCC receiving NCRT in each study.(5-13) Whether the results could be applied to East Asian countries such as China where the incidence of ESCC is extremely high remains to be”
- A Randomized Trial Comparing Postoperative Adjuvant Chemotherapy with Cisplatin and 5-Fluorouracil Versus Preoperative Chemotherapy for Localized Advanced Squamous Cell Carcinoma of the Thoracic Esophagus (JCOG9907) (2011, background): “In Western countries, preoperative chemoradiotherapy is one of the standard treatments, but the results of the JCOG9204 study showed far better survival than that of those trials [2-4].”